🔎 Trials Near Me

መነሻ › ሉኬሚያ › Virginia

በVirginia ለሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለሉኬሚያ የሚደረጉ 7 ጥናቶች በVirginia ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በVirginia ውስጥ ያሉ ከተሞች

Official study text (English)

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 3, Charlottesville
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 71 · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07504458

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Virginia School of Medicine, Charlottesville
  • Virginia Cancer Specialists, Manassas
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • University of Virginia Comprehensive Cancer Center, Charlottesville
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Richmond
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ኦገስ 2026 · NCT06137118

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Charlottesville
  • Dren Investigational Site, Fairfax
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Virginia Commonwealth University/Massey Cancer Center, Richmond
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሜይ 2026 · NCT01790152

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Charlottesville
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።